Gros-30 Injection | Paclitaxel 30 mg/5 mL, Uses & Product Details
Gros-30 Injection contains paclitaxel 30 mg/5 mL, an anticancer prescription medicine manufactured by Emcure Pharmaceuticals. The product packaging identifies it as Paclitaxel Injection IP for intravenous (IV) use and indicates a single-dose vial. Paclitaxel is used in specialist oncology treatment protocols for certain cancers.
Product Details
Product Name: Gros-30 Injection
Active Ingredient: Paclitaxel
Strength: 30 mg/5 mL
Dosage Form: Concentrate or solution for injection, as specified on the product label
Route of Administration: Intravenous (IV)
Pack Type: Single-dose vial
Volume: 5 mL
Manufacturer: Emcure Pharmaceuticals
Therapeutic Class: Antineoplastic agent
Prescription Status: Prescription medicine
About Gros-30 Injection
Gros-30 Injection contains paclitaxel, a chemotherapy medicine belonging to the taxane class. It works by interfering with microtubule function, which is important for cell division. This action helps prevent cancer cells from multiplying.
Paclitaxel may be used in the treatment of certain cancers, including ovarian cancer, breast cancer, non-small-cell lung cancer and other malignancies, depending on the diagnosis and approved treatment protocol.
The dose and treatment schedule are determined by an oncologist based on the type of cancer, body surface area, blood counts, liver function, previous treatment and other clinical factors. Administration must be performed by trained healthcare professionals in an appropriate medical setting.
Important Safety Information
Gros-30 Injection is a specialist chemotherapy medicine and must only be used under the supervision of a qualified oncologist.
Blood-cell suppression: Paclitaxel may reduce blood-cell counts, increasing the risk of infection, anemia and bleeding.
Allergic reactions: Serious hypersensitivity reactions can occur. Appropriate premedication and monitoring may be required according to the treatment protocol.
Nerve-related effects: Peripheral neuropathy, including tingling, numbness or pain in the hands and feet, may occur.
Infusion reactions: Patients require monitoring during administration for breathing difficulties, blood-pressure changes and other infusion-related reactions.
Other possible side effects: These may include hair loss, nausea, fatigue, muscle pain and joint pain.
Do not self-administer this medicine. The treating oncology team must determine the appropriate dose, infusion procedure, monitoring and supportive care.
Frequently Asked Questions
1. What is Gros-30 Injection?
Gros-30 is a paclitaxel injection labeled for intravenous use and supplied in a single-dose vial.
2. What is the active ingredient in Gros-30 Injection?
The active ingredient is paclitaxel 30 mg per 5 mL, as indicated on the product packaging.
3. What is Gros-30 Injection used for?
Paclitaxel is used in specialist chemotherapy protocols for certain cancers. Its suitability depends on the diagnosis and the oncologist's treatment plan.
4. How is Gros-30 Injection administered?
It is administered intravenously by trained healthcare professionals in a suitable medical facility. It must not be self-administered.
5. Does Gros-30 Injection require a prescription?
Yes. Paclitaxel is a prescription chemotherapy medicine that requires specialist medical supervision and appropriate monitoring.
📞 Instant Support – Call / WhatsApp Now
📲 Phone: +91 8007161282
💬 WhatsApp: https://wa.me/918007161282
📲 Phone: +91 9970011496
Contact us for product information, prescription requirements, regulatory requirements and pharmaceutical supply enquiries.
🌐 Visit Our Official Website
https://www.indiamedexport.com/
